|
|
| The
long-term effect of specific type II 5alpha-reductase
inhibition with finasteride on bone mineral density in
men: results of a 4-year placebo controlled trial |
- J Urol 2002 May;167(5):2105-8 (ISSN: 0022-5347)
-
- Matsumoto AM; Tenover L; McClung M; Mobley D; Geller J;
Sullivan M; Grayhack J; Wessells H; Kadmon D; Flanagan M;
Zhang GK; Schmidt J; Taylor AM; Lee M; Waldstreicher J
VA Puget Sound Health Care System and University of Washington,
Seattle, USA; Collective Name: The Pless Study Group.
-
- PURPOSE: We determine the effect of long-term suppression
of dihydrotestosterone with finasteride, a specific type II
5alpha-reductase inhibitor, on bone mineral density.
-
- MATERIALS AND METHODS: As part of a large (3,040
cases) 4-year, double-blind, placebo controlled trial designed
to assess the long-term effects of finasteride in men with
benign prostatic hyperplasia, 157 men 46 to 76 years old who
were randomized to receive either 5 mg. finasteride or placebo
underwent dual energy x-ray absorptiometry of the lumbar spine
at baseline and at years 2, 3 and 4. RESULTS: Of 117 patients
who had a baseline measurement and at least 1 additional measurement
during the study baseline mean plus or minus standard deviation
bone mineral density values were 1.12 +/- 0.17 gm./cm.2 in
the finasteride group (63) and 1.10 +/- 0.17 gm./cm.2 in the
placebo group (54). After 4 years bone mineral density was
not different between treatment groups (finasteride 1.14 +/-
0.17 gm./cm.2 and placebo 1.13 +/- 0.18 gm./cm.2). Similar
results were obtained for the 33 finasteride and 25 placebo
treated patients who completed the study with year 4 bone
mineral density measurements. CONCLUSIONS: These data demonstrate
that long-term inhibition of type II 5alpha-reductase with
finasteride does not adversely affect bone mineral density.
content2 |
|
